siRNAs: Uses, Common Brands, and Safety Info

"siRNAs, a class of RNA interference (RNAi) molecules, offer a promising approach for treating various genetic and acquired diseases. They can target specific genes, inhibit viral replication, and promote tumor cell death. Common brands include Onpattro, Givlaari, and Lumasiran. While generally well-tolerated, they may cause mild side effects. Ongoing research aims to optimize their delivery and enhance their therapeutic potential."


siRNAs, or small interfering RNAs, belong to a class of therapeutic drugs known as RNA interference (RNAi) molecules. RNAi is a natural biological process that regulates gene expression by selectively silencing specific genes. siRNAs are double-stranded RNA molecules that can be designed to target and degrade specific mRNA sequences, thereby inhibiting the production of disease-causing proteins. They offer a promising approach for treating various genetic and acquired diseases.


siRNAs have shown potential in treating a range of diseases, including genetic disorders, viral infections, and certain types of cancers. Research has demonstrated their efficacy in reducing the expression of disease-associated genes, inhibiting viral replication, and promoting tumor cell death. siRNAs can be used both as standalone therapies or in combination with other treatment modalities.

Common Brands

Several pharmaceutical companies have developed siRNA-based drugs to target specific diseases. However, it is important to note that the availability of siRNA-based drugs may vary depending on the region. Some notable brands include:

  • Onpattro (patisiran): Approved for the treatment of hereditary transthyretin-mediated amyloidosis, a condition that affects the nervous system and heart.

  • Givlaari (givosiran): Approved for the treatment of acute hepatic porphyria, a rare genetic disorder that affects the production of heme.

  • Lumasiran: Approved for the treatment of primary hyperoxaluria type 1, a rare genetic disorder that affects the kidneys and urinary tract.


siRNA-based drugs are generally well-tolerated; however, they may be associated with some side effects. Common side effects include injection site reactions, flu-like symptoms, and mild-to-moderate fatigue. As with any medication, it is important to consult with a healthcare professional to determine the appropriate dosage and to monitor for any potential adverse reactions.

It is worth mentioning that the safety and efficacy of siRNAs are constantly being studied and improved. Ongoing research aims to optimize delivery methods, enhance stability, and minimize off-target effects, further enhancing the therapeutic potential of siRNA-based drugs.